US Pharma MarketingParabilis reveals IPO plans the day after Regeneron deal as listings heat up
Parabilis Medicines, the decade-old and well-funded Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy…
Parabilis Medicines, the decade-old and well-funded "undruggable" biotech out of Greg Verdine's Harvard lab, seeks to become the twelfth drug developer to conduct an initial public offering this year.
The biotech
Source: Endpoints News